Clinical Trial

Cardiovascular Structure and Function in the Mucopolysaccharidoses

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study's investigators previously demonstrated the potential utility of non-invasive carotid ultrasonography to calculate carotid intima media thickness (cIMT) and stiffness (as measured by the three parameters, carotid cross-sectional distensibility \[cCSD\], carotid cross-sectional compliance \[cCSC\], and carotid incremental elastic modulus \[cIEM\]) in people with mucopolysaccharidoses (MPS). Investigators also studied arterial gene expression in animal models of MPS, and identified upregulation of a number of markers potentially tied to atherosclerosis and inflammation. These include the atherosclerotic marker known as Clusterin (CLU), Cathepsin S, Elastin, and the inflammatory cytokines interleukin 1-α, interleukin 1-β, interleukin 2, and interleukin 6. Other studies have identified elevation in circulating tumor necrosis factor-α correlating with pain and physical disability in certain mucopolysaccharidoses. Since these studies are cross sectional, and not longitudinal, this study aims to annually measure these previously studied biomarkers (carotid measurements, circulating cytokines, cathepsin S, elastin, and CLU) in a large cohort of MPS patients. This study is a 3-year, prospective, anonymized, longitudinal assessment of cardiovascular structure, function, and circulating biomarkers in patients with mucopolysaccharidoses.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-09-21; most recent amendment 2026-01-05.
Status change: Recruiting → Active, Not Recruiting 2026-01-05
Trial Details
NCT Number NCT05063435
Lead Sponsor Children's Hospital of Orange County
Collaborators: Ultragenyx Pharmaceutical Inc
Conditions Mucopolysaccharidoses, Carotid Disease, Cardiac Disease, Inflammation
Enrollment 30 participants
Start Date 2021-10-13
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-07